PURPOSE: In very elderly cancer patients, health-related quality of life (HRQOL) is a particularly important issue but has rarely been studied due to a lack of specific instruments and of reference data. We performed a prospective analysis of HRQOL in patients ≥80 years undergoing radiotherapy with the newly validated elderly-specific HRQOL module EORTC QLQ-ELD14. METHODS: We prospectively assessed HRQOL in n = 50 radiotherapy patients ≥80 years (32% lung, 20% gastrointestinal, 8% each of breast, head and neck, gynecologic cancer) at the start (t1), end (t2), and 6 months after (t3) radiotherapy, using EORTC QLQ-C30 and EORTC QLQ-ELD14. Overall survival was determined in the whole cohort and subgroups. RESULTS: Median overall survival from the start of radiotherapy was 15 months; 1-year and 2-year overall survival rates were 57.1 and 31.0%, respectively. Eastern Cooperative Oncology Group (ECOG) performance status <2, Charlson comorbidity index ≤6, curative treatment intention, local tumor stage Union Internationale Contre le Cancer (UICC I, II), and total dose >45 Gy were associated with prolonged survival. No significant changes in any HRQOL domain were observed during the course of treatment (t1 to t2). Six months after radiotherapy (t3), a significant and clinically relevant deterioration of HRQOL was seen in EORTC QLQ-C30 for physical function and role function and in EORTC QLQ-ELD14 for future worries, burden of illness, and family support. CONCLUSIONS: In radiotherapy patients ≥80 years, HRQOL was maintained until the end of radiotherapy but deteriorated in general and elderly-specific areas thereafter, suggesting a need to develop specific supportive interventions for this age group.
PURPOSE: In very elderly cancerpatients, health-related quality of life (HRQOL) is a particularly important issue but has rarely been studied due to a lack of specific instruments and of reference data. We performed a prospective analysis of HRQOL in patients ≥80 years undergoing radiotherapy with the newly validated elderly-specific HRQOL module EORTC QLQ-ELD14. METHODS: We prospectively assessed HRQOL in n = 50 radiotherapy patients ≥80 years (32% lung, 20% gastrointestinal, 8% each of breast, head and neck, gynecologic cancer) at the start (t1), end (t2), and 6 months after (t3) radiotherapy, using EORTC QLQ-C30 and EORTC QLQ-ELD14. Overall survival was determined in the whole cohort and subgroups. RESULTS: Median overall survival from the start of radiotherapy was 15 months; 1-year and 2-year overall survival rates were 57.1 and 31.0%, respectively. Eastern Cooperative Oncology Group (ECOG) performance status <2, Charlson comorbidity index ≤6, curative treatment intention, local tumor stage Union Internationale Contre le Cancer (UICC I, II), and total dose >45 Gy were associated with prolonged survival. No significant changes in any HRQOL domain were observed during the course of treatment (t1 to t2). Six months after radiotherapy (t3), a significant and clinically relevant deterioration of HRQOL was seen in EORTC QLQ-C30 for physical function and role function and in EORTC QLQ-ELD14 for future worries, burden of illness, and family support. CONCLUSIONS: In radiotherapy patients ≥80 years, HRQOL was maintained until the end of radiotherapy but deteriorated in general and elderly-specific areas thereafter, suggesting a need to develop specific supportive interventions for this age group.
Authors: Allen M Chen; D Gregory Farwell; Quang Luu; Esther G Vazquez; Derick H Lau; James A Purdy Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-31 Impact factor: 7.038
Authors: K Cocks; M T King; G Velikova; G de Castro; M Martyn St-James; P M Fayers; J M Brown Journal: Eur J Cancer Date: 2012-03-12 Impact factor: 9.162
Authors: H Ikeda; S Ishikura; M Oguchi; H Niibe; A Yorozu; K Nakano; N Fuwa; S Watanabe; T Teshima Journal: Jpn J Clin Oncol Date: 1999-08 Impact factor: 3.019
Authors: Ans J C M Vulto; Valery E P P Lemmens; Marieke W J Louwman; Maryska L G Janssen-Heijnen; Philip H P Poortmans; Marnix L M Lybeert; Jan Willem W Coebergh Journal: Cancer Date: 2006-06-15 Impact factor: 6.860
Authors: Martine T E Puts; Johanne Monette; Veronique Girre; Christina Wolfson; Michèle Monette; Gerald Batist; Howard Bergman Journal: Support Care Cancer Date: 2012-09-01 Impact factor: 3.603
Authors: Eni Shehu; Sigrid Roggendorf; André Golla; Antonia Koenig; Gabriele I Stangl; Andrea Diestelhorst; Daniel Medenwald; Dirk Vordermark; Anke Steckelberg; Heike Schmidt Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575